Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Lipidology

Advanced Therapies for Severe and Homozygous FH

At a Glance

For homozygous familial hypercholesterolemia, evinacumab, lomitapide, and lipoprotein apheresis can lower LDL cholesterol when standard medicines are not enough. These intensive treatments require specialist supervision, diet support, and regular monitoring.

For those diagnosed with Homozygous Familial Hypercholesterolemia (HoFH) or extremely severe, refractory Heterozygous FH (HeFH), standard treatments like statins and PCSK9 inhibitors may not be enough [1]. This is because these medications typically rely on the body’s LDL receptors (the liver’s “docking stations”) to clear cholesterol [2]. In HoFH, these docking stations are often severely broken or completely missing (often called receptor-null), meaning the medications have diminished effect [3][1].

To manage HoFH, specialists use advanced, LDLR-independent therapies that clear cholesterol through different biological pathways [4][5].

Evinacumab

Evinacumab is an injectable medication specifically indicated for HoFH (it is not a routine treatment for HeFH) [6].

  • How it works: It blocks a protein called ANGPTL3. By doing so, it helps the body break down cholesterol-carrying particles without needing functioning LDL receptors [4].
  • Effectiveness: In clinical trials, it reduced LDL-C by an average of 47% to 49% in HoFH patients [7][3].
  • Administration: It is an intravenous (IV) infusion given once every four weeks [6]. Depending on the jurisdiction, it is approved for adults and, in some countries like the US, children as young as 5 years old with HoFH [6][8]. Infusion-related reactions can occur.

Lomitapide

Lomitapide is a daily capsule generally used for adult HoFH that targets how the body produces cholesterol [5].

  • How it works: It inhibits a protein in the liver and intestines (MTP) essential for packaging cholesterol into blood particles [9].
  • Strict Dietary Requirements: To prevent severe gastrointestinal issues and liver fat buildup, you must follow a very strict low-fat diet (less than 20% of total calories from fat). This diet must be guided by a specialist dietitian and should not be self-imposed [10][11].
  • Monitoring and Risks: Lomitapide carries significant risks of elevating liver enzymes (transaminases) and causing hepatic steatosis (fatty liver). It also requires careful attention to drug interactions, embryo-fetal toxicity risks in pregnancy, and prescription of fat-soluble vitamin supplements [12][13].

Lipoprotein Apheresis

Lipoprotein apheresis is a physical process, similar to kidney dialysis, that removes LDL cholesterol directly from the blood [14].

  • The Process: Blood or plasma is removed through a vascular access line, passed through a specialized filter that traps the LDL, and returned to the body. It requires anticoagulation and can sometimes cause temporary low blood pressure (hypotension) [15].
  • Frequency and Impact: Sessions typically happen every 1 to 2 weeks and take several hours [16][17]. While it can severely drop LDL levels immediately after the session, the cholesterol inevitably rebounds between sessions [18]. Therefore, clinicians assess time-averaged LDL-C to gauge success [19][20].

The Importance of Specialized Care

Because HoFH is so rare and the treatments carry heavy burdens and risks, it is essential to be cared for at a specialized lipid center [21]. These centers have the expertise to manage drug side effects, coordinate dietitians, and handle the significant time commitments and vascular access needs for apheresis [20][9][22]. While intensive, these therapies offer pathways to manage cholesterol levels that were once thought impossible for people with HoFH [23].

Common questions in this guide

What advanced treatments are available for homozygous familial hypercholesterolemia?
For HoFH or exceptionally severe, treatment-resistant HeFH, specialists may consider evinacumab, lomitapide, or lipoprotein apheresis when standard medicines do not lower LDL enough. The best plan depends on factors such as age, LDL level, genetic receptor activity, treatment risks, and access to specialized care.
How does evinacumab lower LDL in HoFH?
Evinacumab blocks ANGPTL3, helping the body break down cholesterol-carrying particles without relying on working LDL receptors. It is given by intravenous infusion every four weeks and is specifically used for HoFH; approved ages vary by country.
What should I know before starting lomitapide?
Lomitapide is a daily capsule that reduces the packaging of cholesterol into blood particles. It requires a specialist-guided diet with less than 20% of calories from fat, liver enzyme and liver-fat monitoring, attention to drug interactions, fat-soluble vitamin supplements, and pregnancy precautions.
How often is lipoprotein apheresis needed for HoFH?
Apheresis usually takes several hours every one to two weeks, using a vascular access line to remove LDL from blood and return the treated blood or plasma. LDL can rise again between sessions, so clinicians often judge its benefit using time-averaged LDL levels rather than the immediate post-treatment result; temporary low blood pressure can occur.
Why should advanced FH treatment be managed at a specialized lipid center?
HoFH is rare, and these treatments require coordinated monitoring, diet support, management of side effects, and specialized equipment or vascular access for apheresis. A lipid center can help patients and families weigh benefits, risks, travel, and the long-term time commitment.
How does my doctor know whether apheresis is working?
Apheresis can lower LDL dramatically right after a session, but the level usually rebounds before the next session. The care team may therefore use time-averaged LDL cholesterol to assess its overall effect instead of relying only on the number immediately after treatment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my (or my child's) specific genetic mutation, and does it mean we have 'null' receptor activity or 'defective' activity?
  2. 2.Given my child's current LDL level, is it time to move beyond standard medications to an LDLR-independent therapy like evinacumab?
  3. 3.Can you explain the long-term monitoring required for lomitapide, specifically how we will check for liver fat buildup?
  4. 4.If we start lipoprotein apheresis, how will you evaluate its effectiveness over time rather than just looking at the number immediately after the procedure?
  5. 5.Does our local hospital have the specialized equipment for pediatric apheresis, or do we need to travel to a dedicated lipid center?
  6. 6.How will you coordinate my care with a specialized dietitian to ensure I'm meeting the strict fat requirements for lomitapide?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Assessment of LDL receptor-dependent lipid lowering therapies in patients with homozygous familial hypercholesterolemia according to functional genotype.

    Mancini GBJ, Ryomoto A, Ruel I, et al.

    Atherosclerosis 2026; (414()):120646 doi:10.1016/j.atherosclerosis.2026.120646.

    PMID: 41643340
  2. 2

    New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.

    Gaudet D, Larouche M, Raal FJ, Catapano AL

    Circulation research 2026; (138(12)):e327270 doi:10.1161/CIRCRESAHA.126.327270.

    PMID: 42241517
  3. 3

    The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia.

    Raal FJ, Rosenson RS, Reeskamp LF, et al.

    JACC. Advances 2023; (2(9)):100648 doi:10.1016/j.jacadv.2023.100648.

    PMID: 38938723
  4. 4

    Evinacumab: Mechanism of action, clinical, and translational science.

    Dingman R, Bihorel S, Gusarova V, et al.

    Clinical and translational science 2024; (17(6)):e13836 doi:10.1111/cts.13836.

    PMID: 38845393
  5. 5

    Lomitapide: a review of its clinical use, efficacy, and tolerability.

    Alonso R, Cuevas A, Mata P

    Core evidence 2019; (14()):19-30 doi:10.2147/CE.S174169.

    PMID: 31308834
  6. 6

    Evinacumab: First Approval.

    Markham A

    Drugs 2021; (81(9)):1101-1105 doi:10.1007/s40265-021-01516-y.

    PMID: 34003472
  7. 7

    Evinacumab for Homozygous Familial Hypercholesterolemia.

    Raal FJ, Rosenson RS, Reeskamp LF, et al.

    The New England journal of medicine 2020; (383(8)):711-720 doi:10.1056/NEJMoa2004215.

    PMID: 32813947
  8. 8

    Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.

    Wiegman A, Greber-Platzer S, Ali S, et al.

    Circulation 2024; (149(5)):343-353 doi:10.1161/CIRCULATIONAHA.123.065529.

    PMID: 37860863
  9. 9

    Long-term experience with lomitapide treatment in patients with homozygous familial hypercholesterolemia: Over 10 years of efficacy and safety data.

    Arca M, D'Erasmo L, Cuchel M, et al.

    Journal of clinical lipidology 2025; (19(4)):775-789 doi:10.1016/j.jacl.2025.03.015.

    PMID: 40494715
  10. 10

    Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide.

    Roeters van Lennep J, Averna M, Alonso R

    Journal of clinical lipidology 2015; (9(4)):607-17.

    PMID: 26228681
  11. 11

    Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia.

    Kameyama N, Maruyama C, Kitagawa F, et al.

    Journal of atherosclerosis and thrombosis 2019; (26(1)):72-83 doi:10.5551/jat.44107.

    PMID: 29899183
  12. 12

    Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia.

    Larrey D, D'Erasmo L, O'Brien S, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2023; (43(2)):413-423 doi:10.1111/liv.15497.

    PMID: 36520008
  13. 13

    Atherosclerotic plaque regression in homozygous familial hypercholesterolaemia: a case report of a long-term lipid-lowering therapy involving LDL-receptor-independent mechanisms.

    Khoury E, Lauzière A, Raal FJ, et al.

    European heart journal. Case reports 2023; (7(1)):ytad029 doi:10.1093/ehjcr/ytad029.

    PMID: 36727130
  14. 14

    Familial Hypercholesterolemia and Lipoprotein Apheresis.

    Makino H, Koezuka R, Tamanaha T, et al.

    Journal of atherosclerosis and thrombosis 2019; (26(8)):679-687 doi:10.5551/jat.RV17033.

    PMID: 31231083
  15. 15

    The scientific basis and future of lipoprotein apheresis.

    Thompson GR

    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2022; (26(1)):32-36 doi:10.1111/1744-9987.13716.

    PMID: 34331508
  16. 16

    A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry).

    Kayikcioglu M, Tokgozoglu L, Yilmaz M, et al.

    Atherosclerosis 2018; (270()):42-48 doi:10.1016/j.atherosclerosis.2018.01.034.

    PMID: 29407887
  17. 17

    Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand.

    Page MM, Ekinci EI, Burnett JR, et al.

    Journal of clinical apheresis 2021; (36(1)):48-58 doi:10.1002/jca.21839.

    PMID: 32911577
  18. 18

    The efficacy of double filtration plasmapheresis in the treatment of homozygous familial hypercholesterolemia: A single-center experience.

    Albayrak M, Yıldız A, Ateş N, Pala Ç

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2019; (58(1)):61-64 doi:10.1016/j.transci.2018.11.007.

    PMID: 30545658
  19. 19

    Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review.

    Luirink IK, Determeijer J, Hutten BA, et al.

    Journal of clinical lipidology 2019; (13(1)):31-39 doi:10.1016/j.jacl.2018.10.011.

    PMID: 30553758
  20. 20

    Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.

    Klaus G, Taylan C, Büscher R, et al.

    Pediatric nephrology (Berlin, Germany) 2018; (33(7)):1199-1208 doi:10.1007/s00467-018-3906-6.

    PMID: 29502162
  21. 21

    2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance.

    Cuchel M, Raal FJ, Hegele RA, et al.

    European heart journal 2023; (44(25)):2277-2291 doi:10.1093/eurheartj/ehad197.

    PMID: 37130090
  22. 22

    Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis.

    Blom DJ, Raal FJ, Santos RD, Marais AD

    Current atherosclerosis reports 2019; (21(12)):48 doi:10.1007/s11883-019-0809-3.

    PMID: 31741187
  23. 23

    Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective-Brief Report.

    Wilkinson MJ, Bijlani P, Davidson MH, et al.

    Arteriosclerosis, thrombosis, and vascular biology 2025; (45(7)):1310-1315 doi:10.1161/ATVBAHA.124.322364.

    PMID: 40438928

This page is for informational purposes only and does not constitute medical advice. A lipid specialist should guide treatment selection, diet, monitoring, and pregnancy-related decisions for severe or homozygous familial hypercholesterolemia.

Get notified when new evidence is published on Familial hypercholesterolemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.